Burris, H. A., LoRusso, P., Jones, S., Guthrie, T. M., Orr, J. B., Williams, D. D., … Sabry, J. (2004). Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. In Journal of Clinical Oncology (Vol. 22). American Society of Clinical Oncology.

Burris, H. A., P. LoRusso, S. Jones, T. M. Guthrie, J. B. Orr, D. D. Williams, J. P. Hodge, Margaret Bush, and J. Sabry. “Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days.” In Journal of Clinical Oncology, Vol. 22. American Society of Clinical Oncology, 2004.

Burris HA, LoRusso P, Jones S, Guthrie TM, Orr JB, Williams DD, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. In: Journal of Clinical Oncology. American Society of Clinical Oncology; 2004.

Burris, H. A., et al. “Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days.” Journal of Clinical Oncology, vol. 22, no. 14S, American Society of Clinical Oncology, 2004.

Burris HA, LoRusso P, Jones S, Guthrie TM, Orr JB, Williams DD, Hodge JP, Bush M, Sabry J. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. Journal of Clinical Oncology. American Society of Clinical Oncology; 2004.